OpportunityAnalyzer: Respiratory Syncytial Virus (RSV) – Opportunity Analysis and Forecasts to 2024
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Human respiratory syncytial virus (RSV) is an enveloped, single-stranded, negative-sense ribonucleic acid (RNA) pneumovirus belonging to the family of Paramyxoviridae. The virus was discovered in 1956, first as an isolate from a laboratory chimpanzee displaying symptoms of the common cold, and later from infants suffering from respiratory disease. RSV can cause upper respiratory tract infections (the common cold) and is the most important cause of lower respiratory tract infections, such as bronchiolitis and pneumonia, in infants. RSV is also an important cause of hospitalizations and deaths in elderly adults.
Today, Medimmune’s Synagis (palivizumab) is the only licensed intervention for the prevention of RSV in infants at a high risk of severe infection. This humanized, mouse monoclonal antibody (mAb) was first approval in 1998, and while it is an efficacious prophylactic intervention, its short 20-day half-life necessitates monthly dosing during the RSV season. Moreover, the high cost of Synagis limits its use to certain subgroups of infants who are at high risk of severe RSV infection, and it is not indicated for use in elderly adults, leaving a key population of high-risk individuals unprotected. Furthermore, due to the absence of effective RSV-specific antivirals, the treatment of RSV infections is largely restricted to a number of supportive treatment options. GlobalData projects the global RSV marketplace — which, for the purposes of this report, comprises the seven major pharmaceutical markets (7MM; US, France, Germany, Italy, Spain, UK, Japan) — to experience unprecedented growth from 2014–2024, driven by the arrival of novel approaches to prevention and management of RSV.
Scope
Overview of RSV infections, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
Topline RSV market revenue from 2014–2024. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting RSV product sales in the 7MM.
Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
Analysis of the current and future market competition in the global RSV market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Key Highlights
Based on interviews with key opinion leaders (KOLs), GlobalData has identified the major unmet needs in the RSV marketplace. Will the leading pipeline agents fulfil these unmet needs during the forecast period (2014–2024)?
What research and development (R&D) strategies will companies leverage to compete in the future RSV marketplace?
Which patient population(s) are most likely to be targeted by novel RSV prophylactic and therapeutic agents?
What clinical and commercial factors are likely to influence RSV product uptake in the 7MM?
Novavax
GlaxoSmithKline
Regeneron
Janssen (Johnson & Johnson)
Gilead Sciences
Ablynx
*All listed companies have at least 1 product included in GlobalData’s epidemiology-based, 10-year drug sales forecast model.
Other Companies Mentioned
Ark Biosciences
Biota Pharmaceuticals
Romark Laboratories
Spring Bank Pharmaceuticals
Immunovaccine, Inc.
Crucell
Bavarian Nordic
Meda Pharmaceuticals
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Infectious Disease reports

